Journal article
Impact of acquired del(17p) in multiple myeloma
Blood advances, v 3(13), pp 1930-1938
09 Jul 2019
PMID: 31248884
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The high-risk abnormality del(17p) can be detected by fluorescence in situ hybridization on malignant plasma cells (PCs) and has an adverse prognostic impact in patients with multiple myeloma (MM). Patients with del(17p) have reduced overall survival (OS). Patients who acquire del(17p) later during the disease course are not well described. The disease characteristics at diagnosis predicting for acquired del(17p) and its overall impact on patient survival is not known. We compared 76 patients with MM who were negative for del(17p) at diagnosis and acquired it later with 152 control MM patients who did not acquire del(17p) at a comparable time point. Patients acquired del(17p) at a median of 35.6 months (range, 4.6-116.1 months) from diagnosis of MM after a median of 2 lines of therapy (range, 1-10 lines of therapy). When compared with controls, patients with acquired del(17p) had shorter median progression-free survival (PFS) (30.1 vs 23.0 months; P = .032) and OS (106.1 vs 68.2 months; P < .001) from diagnosis. After the detection of del(17p), the median PFS was 5.4 months and the median OS was 18.1 months. High lactate dehydrogenase level (odds ratio [OR], 3.69; 95% confidence interval [CI], 1.11-12.24) and presence of t(4;14) (OR, 2.66; 95% CI, 1.09-6.48) or any high-risk translocation (OR, 2.23; 95% CI, 1.00-4.95) at diagnosis predicted acquisition of del(17p). High PC proliferative rate predicted shorter OS from detection of del(17p) (hazard ratio, 2.28; 95% CI, 1.31-3.96; P = .004). Our study shows that acquisition of del(17p) is an important molecular event associated with reduction in OS in MM. Certain baseline factors may predict acquisition of del(17p). This needs validation in prospective data sets.
Metrics
Details
- Title
- Impact of acquired del(17p) in multiple myeloma
- Creators
- Arjun Lakshman - Mayo Clinic in ArizonaUtkarsh Painuly - University Hospital Hradec KrálovéS. Vincent Rajkumar - Mayo Clinic in ArizonaRhett P. Ketterling - Mayo Clinic in ArizonaPrashant Kapoor - Mayo Clinic in ArizonaPatricia T. Greipp - Mayo Clinic in ArizonaAngela Dispenzieri - Mayo Clinic in ArizonaMorie A. Gertz - Mayo Clinic in ArizonaFrancis K. Buadi - Mayo Clinic in ArizonaMartha Q. Lacy - Mayo Clinic in ArizonaDavid Dingli - Mayo Clinic in ArizonaArnie L. Fonder - Mayo Clin, Div Hematol, 200 First St SW, Rochester, MN 55905 USASuzanne R. Hayman - Mayo Clinic in ArizonaMiriam A. Hobbs - Mayo Clinic in ArizonaWilson Gonsalves - Mayo Clinic in ArizonaYi Lisa Hwa - Mayo Clinic in ArizonaNelson Leung - Mayo Clinic in ArizonaRonald S. Go - Mayo Clinic in ArizonaYi Lin - Mayo Clinic in ArizonaTaxiarchis Kourelis - Mayo Clinic in ArizonaRahma Warsame - Mayo Clinic in ArizonaJohn A. Lust - Mayo Clinic in ArizonaStephen J. Russell - Mayo Clinic in ArizonaSteven R. Zeldenrust - Mayo Clinic in ArizonaRobert A. Kyle - Mayo Clinic in ArizonaShaji K. Kumar - Mayo Clinic in Arizona
- Publication Details
- Blood advances, v 3(13), pp 1930-1938
- Publisher
- Elsevier
- Number of pages
- 9
- Grant note
- NCI CA186781 / National Institutes of Health, National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000474653700002
- Scopus ID
- 2-s2.0-85068841654
- Other Identifier
- 991022059810204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Hematology